Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147537 · ClinicalTrials.gov registry record · Phase 1
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 282
- Enrollment target
NCT00147537 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 282 participants.
The verdict
NCT00147537, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 282 participants
- Enrollment target
Study Summary
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2005-02 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147537
The ClinicalTrials.gov registry entry for NCT00147537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00147537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00147537 about?
NCT00147537 is a clinical study titled "Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer". Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, ...
What is the current status of trial NCT00147537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 282 participants. The study started on 2005-02. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00147537?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT00147537?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.